|
10.09.2015 19:24:00
|
Amdipharm Mercury Debtco Limited -- Moody's places all ratings of AMCo under review with direction uncertain
Frankfurt am Main, September 10, 2015 -- Moody's Investors Service, ("Moody's") has today placed the B3 Corporate Family Rating, B3-PD Probability of Default Rating and all other associated debt ratings of Amdipharm Mercury Debtco Limited ('AMCo') under review with direction uncertain. This follows the announcement by Concordia Healthcare Corp. of its intention to acquire AMCo from Cinven and certain other sellers and Moody's expectation that AMCo's rated debt will be redeemed in conjunction with the closing of the proposed transaction.
Letzte Top-Ranking Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.